Mezzion’s new kidney disease data sent shares higher, but the decisive test is still ahead
Mezzion reports animal-model ADPKD data for udenafil as it prepares Phase 2b testing. The findings support development, but human efficacy is unproven.
Pharma & Biotech
Medical Devices & Diagnostics
EndoQuest’s ELS robot posted striking early resection results. What will the FDA demand next?
EndoQuest completes PARADIGM enrollment with encouraging preliminary ESD results, setting up a critical FDA De Novo submission.
Medical Devices & Diagnostics
How UpDoc’s clinical AI could transform insulin management without replacing physicians
UpDoc is moving patient-facing artificial intelligence beyond reminders and administrative support into insulin management. Its narrow FDA clearance, physician-defined limits and early clinical evidence reveal both the potential and the boundaries of autonomous chronic-disease care.
Pharma & Biotech
Syntax Bio funding boost puts pancreatic beta cell therapy closer to preclinical test
Find out how Syntax Bio’s expanded Series A could shape Cellgorithm-based beta cell therapy for type 1 diabetes.
Pharma & Biotech
Why Pendulum Therapeutics is taking its microbiome platform beyond metabolic health with Mayo Clinic
Pendulum Therapeutics has expanded its Mayo Clinic collaboration into women’s health and dermatology. Read what this could mean for microbiome medicine.
Medical Devices & Diagnostics
What Anumana’s FDA-cleared pulmonary hypertension algorithm means for cardiovascular AI
Anumana won FDA clearance for an ECG-AI pulmonary hypertension tool. Read what it changes for diagnosis, workflow adoption, and cardiovascular AI strategy.
Medical Devices & Diagnostics
Detect-ION, Mayo Clinic join forces to develop non-invasive pneumonia breath test
Detect-ION, a diagnostics-focused startup based in Tampa, Florida, has announced a collaborative project with the Infectious Diseases Division at Mayo Clinic Florida to develop a non-invasive breath test for detecting Pseudomonas aeruginosa, a leading cause of pneumonia in vulnerable patient populations. Funded through the Mayo Clinic Advanced Innovation Research program, the project aims to address